Cabaletta Bio, Inc.CABANASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 91% recommend buying.

Consensus Rating

Buy

11 analysts·Moderate coverage

91%

Rating Distribution

Strong Buy

00%

Buy

1091%

Hold

19%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 601% higher.

Bear Case

$3.00

+29%

Consensus

$16.33

+601%

Bull Case

$32.00

+1273%

Price Range11 analysts

Low

Consensus

High

$3.00

$32.00

Current Target

Current Price

$2.33

Upside to Target

$14.00

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-1.77(5 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev-71.50%

EPS—

FY2028

Rev+17132.14%

EPS—

FY2029

Rev+255.08%

EPS—

Earnings Surprises

Beat rate:33%(4/12 quarters)

Avg surprise:-0.6%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Mar 21, 2024Stifel Nicolaus

Cabaletta Bio Inc. (CABA) PT Raised to $32 at Stifel

Target:$32.00

+82.4%from $17.54

Jan 3, 2023Wells Fargo

Wells Fargo Maintains Overweight on Cabaletta Bio, Raises Price Target to $14

Target:$14.00

+50.5%from $9.30

Aug 30, 2022Morgan Stanley

Cabaletta Bio downgraded to Equal Weight from Overweight at Morgan Stanley

Target:$3.00

+139.0%from $1.25

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance